DoctorNibu Parameswaran Nair

Adjunct Lecturer

Pharmacy

  • Adjunct Lecturer
    Pharmacy
  • 03 6226 1854 (Work)
  • School of Pharmacy and Pharmacology, Pharmacy, 4007 School of Pharmacy and Pharmacology, Sandy Bay Campus, TAS

RESEARCH SUMMARy

Research Themes

Nibu’s research aligns to the University’s research theme of Better Health. With his strong background in Clinical Pharmacy practice, Nibu has an ongoing interest in a wide range of projects involving identifying drug-related problems in the hospital setting, pharmacovigilance studies in the elderly and quality use of medicines. His particular research area is in the prevention of adverse drug reactions in the elderly and intensive monitoring studies in drug safety.

Awards

1. Awarded Postdoctoral Research Fellowship in Medication Safety from the School of Pharmacy and Pharmacology, University of Tasmania, Australia.
2. A scientific paper entitled ‘Repeat Adverse Drug Reaction-related Hospital Admissions in Elderly Australians’ was awarded the best student presentation in the poster session of ISPOR 22nd Annual International Meeting, 20-24 May 2017, Boston, USA.
3. Doctoral Scholarship for PhD from the School of Pharmacy and Pharmacology, University of Tasmania, Australia.

Current projects

1. Preventing Adverse Drug Reactions After Discharge

2. Adverse drug reaction-related hospital admission in older Australians with dementia

FUNDED PROJECTS

  • GRANT
    Adverse drug reaction-related hospital admission in elderly Australians with dementia
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Parameswaran Nair N,
    • Bereznicki L,
    • Adamczewski B,
    • Salahudeen M,
    • Bereznicki B
    Project Total: $9,985; Dementia is a significant risk factor for serious side effects of medicines or adverse drug reactions (ADRs). This prospective study will investigate and identify the prevalence and risk factors for ADR-related hospital admissions in elderly patients with dementia or cognitive impairment. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • GRANT
    Preventing Adverse Drug Reactions in the Elderly
    1 Jan 2019 - 30 Jun 2023
    People funded by this grant:
    • Bereznicki L,
    • Curtain C,
    • Bereznicki B,
    • Cousins J,
    • Connolly M
    Project Total: $274,000; Based on our prospective adverse drug reaction (ADR) registry:1 * 15% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related, * 89% were preventable, * 17% patients had a repeat ADR within 12 months, and * One third of patients with repeat ADRs experienced the same ADR caused by the same medications. From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2 We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation. Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania. Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups. Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined. Recommendations will relate to: * post-discharge medication management services, * monitoring of specific parameters/medications, and * de-prescribing strategies. The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patient's GP, alongside the usual information, in the electronic discharge summary. Control: Usual hospital care, with GPs receiving the standard discharge summary. Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received. Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome Funded by: Hospitals Contribution Fund Research Foundation - HCF - Grant-Health Services Research Program ($274,000); University of Tasmania.